DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tb6j2p/methotrexate) has announced the addition of the "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.
The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Originally developed as a cancer therapy, MTX has become the leading DMARD in most countries because of its rapid onset of action and low cost. MTX is an antineoplastic antimetabolite with immunosuppressant actions. Its use for the treatment of RA began in the 1970s, as it had been shown to sustain benefits for at least 50% of RA patients. MTX is an antagonist of folic acid metabolism, and its effects in inflammatory diseases may be secondary to the induction of adenosine release and the inhibition of polyamines.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Methotrexate (Numerous Brands)
7 Appendix
For more information visit http://www.researchandmarkets.com/research/tb6j2p/methotrexate
